Simulect and Disseminated intravascular coagulation - a phase IV clinical study of FDA data

Summary:

Disseminated intravascular coagulation is reported as a side effect among people who take Simulect (basiliximab), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Cellcept, and have Herpes zoster.

The phase IV clinical study analyzes which people have Disseminated intravascular coagulation when taking Simulect. It is created by eHealthMe based on reports of 3,859 people who have side effects when taking Simulect from the FDA, and is updated regularly.

What is Simulect?

Simulect has active ingredients of basiliximab. eHealthMe is studying from 3,861 Simulect users. Check the latest studies of Simulect.

What is Disseminated intravascular coagulation?

Disseminated intravascular coagulation (systemic activation of blood coagulation) is found to be associated with 1,166 drugs and 1,771 conditions by eHealthMe. Check the latest studies of Disseminated intravascular coagulation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

3,859 people reported to have side effects when taking Simulect.
Among them, 50 people (1.3%) have Disseminated intravascular coagulation.

Could Simulect cause Disseminated intravascular coagulation?

Among these 50 people:

How long have people been on Simulect when they have Disseminated intravascular coagulation? *

What is the gender of people who have Disseminated intravascular coagulation when taking Simulect? *

female: 40 %
male: 60 %

What is the age of people who have Disseminated intravascular coagulation when taking Simulect? *

What are other drugs people take besides Simulect? *

What are other side effects people have besides Disseminated intravascular coagulation? *

Thrombocytopenia (decrease of platelets in blood): 12 people, 24.00%
Fever: 12 people, 24.00%
Kidney Transplant Rejection: 10 people, 20.00%
Abdominal Pain: 9 people, 18.00%
Cardiac Arrest: 9 people, 18.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 8 people, 16.00%
Hyperkalemia (damage to or disease of the kidney): 8 people, 16.00%
Depressed Level Of Consciousness: 7 people, 14.00%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 6 people, 12.00%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 6 people, 12.00%

What are the existing conditions these people have? *

Immunodeficiency Disorders: 4 people, 8.00%
Herpes Zoster: 4 people, 8.00%
High Blood Pressure: 1 person, 2.00%

* Approximation only. Some reports may have incomplete information.

Do you take Simulect and have Disseminated intravascular coagulation?

- Check whether Disseminated intravascular coagulation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Simulect:

Simulect (3,861 reports)

Disseminated intravascular coagulation treatments and more:

Disseminated intravascular coagulation (24,199 reports)

How severe was Disseminated intravascular coagulation and when was it recovered:

Disseminated intravascular coagulation in Simulect

Expand to all the drugs that have ingredients of basiliximab:

Disseminated intravascular coagulation and drugs with ingredients of basiliximab

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Simulect:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disseminated intravascular coagulation:

Disseminated intravascular coagulation (1,166 drugs)

Browse all the conditions that are associated with Disseminated intravascular coagulation:

Disseminated intravascular coagulation (1,771 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on basiliximab (the active ingredients of Simulect) and Simulect (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.